Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information

Background: To assess the cost-effectiveness of trabectedin compared with end-stage treatment (EST) after failure with anthracycline and/or ifosfamide in metastatic soft tissue sarcoma (mSTS). Design: Analysis was carried out using a probabilistic Markov model with trabectedin → EST and EST arms, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Soini, E. J. O., García San Andrés, B., Joensuu, T.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003615/
https://www.ncbi.nlm.nih.gov/pubmed/20627875
http://dx.doi.org/10.1093/annonc/mdq339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003615/
https://www.ncbi.nlm.nih.gov/pubmed/20627875
http://dx.doi.org/10.1093/annonc/mdq339

Ejemplares similares